HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report) traded up 1.6% on Thursday . The company traded as high as $2.54 and last traded at $2.54. 1,700 shares were traded during trading, a decline of 62% from the average session volume of 4,473 shares. The stock had previously closed at $2.50.
HLS Therapeutics Stock Performance
The stock has a 50-day simple moving average of $2.54 and a two-hundred day simple moving average of $2.66.
About HLS Therapeutics
HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.
Recommended Stories
- Five stocks we like better than HLS Therapeutics
- Breakout Stocks: What They Are and How to Identify Them
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- What is a Death Cross in Stocks?
- MarketBeat Week in Review – 11/4 – 11/8
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
